IOM-Report-Breast-Cancer-And-The
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Human T-Cell Lymphotropic Virus Type II Infection (Letter to the Editor)
HUMAN T-CELL L YMPHOTROPIC VIRUSES 1. Exposure Data 1.1 Structure, taxonomy and biology 1.1.1 Structure The structure of retroviruses is reviewed in the monograph on human immuno- deficiency viruses (HIV) in this volume. The human T-cell lymphotropic (T-cell Ieu- kaemia/lymphoma) viruses (HTL V) are enveloped viruses with a diameter of approxi- mately 80-100 nm (Figure 1). The HTLV virions contain two covalently bound genomic RNA strands, which are complexed with the viral enzymes reverse transcriptase (RT; with associated RNase H activity), integrase and protease and the capsid proteins. The outer part of the virions consists of a membrane-associated matrix protein and a lipid Iayer intersected by the envelope proteins (GeIderbIom, 1991). Figure 1. An electron micrograph of HTL V -1 virus Courtes y of Dr Bernard Kramarsky, Advanced Biotechnologies, Inc., Columbia, MD, USA 1.1.2 T axonomy and phylogeny Traditionally, retroviruses (family Retroviridae) have been cIassified according to a combination of criteria incIuding disease association, morphoIogy and cytopathic effects in vitro. On this basis three subfamiIies were defined. The oncoviruses (Greek, onkos = mass, swelling) consist of four morphological subtypes which are associated with tumours in naturally or experimentally infected animaIs, and non-oncogenic related viruses. The second group, the Ientiviruses (Latin, lentus = slow), cause a variety of diseases including immunodeficiency and wasting syndromes, usually after a long period -261- 262 IARC MONOGRAPHS VOLUME 67 of clinical latency. The third subfamily, the spumaviruses (Latin, spuma = foam), so called because of the characteristic 'foamy' appearance induced in infected cells in vitro, have not been conclusively 1inked to any disease. -
Teaching and Learning About the Holocaust
RECOMMENDATIONS FOR TEACHING AND LEARNING ABOUT THE HOLOCAUST INTERNATIONAL HOLOCAUST REMEMBRANCE ALLIANCE RECOMANDĂRI PRIVIND PREDAREA ŞI ÎNVĂȚAREA DESPRE HOLOCAUST Cover image: Participants at Salzburg Global Seminar’s Holocaust Education and Genocide Prevention Session discuss IHRA teaching guidelines in 2015. Credit: Salzburg Global Seminar. Copertă: Participanţi la sesiunea referitoare la educaţia privind Holocaustul şi prevenirea genocidului, a Seminarului Global de la Salzburg, discută liniile directoare ale IHRA în 2015. Sursa: Salzburg Global Seminar RECOMMENDATIONS FOR TEACHING AND LEARNING ABOUT THE HOLOCAUST INTERNATIONAL HOLOCAUST REMEMBRANCE ALLIANCE RECOMANDĂRI PRIVIND PREDAREA ŞI ÎNVĂȚAREA DESPRE HOLOCAUST First edition published in 2019 by the International Holocaust Remembrance Alliance (IHRA) © 2019 IHRA All rights reserved. The contents of this publication may be freely used and copied for educational and other non-commercial purposes, provided that any such reproduction is accompanied by an acknowledgement of the IHRA as the source. Prima ediție a fost publicată în 2019 de către Alianța Internațională pentru Memoria Holocaustului (IHRA) © 2019 IHRA Toate drepturile rezervate. Conținutul acestei publicații poate fi utilizat în mod liber și multiplicat/copiat în scopuri educaționale și alte scopuri ne-comerciale, cu condiția ca orice astfel de multiplicări să fie însoțite de indicarea IHRA ca sursă. ABOUT THE IHRA The International Holocaust Remembrance Alliance (IHRA) unites governments and experts to strengthen, advance and promote Holocaust education, research and remembrance and to uphold the commitments of the 2000 Stockholm Declaration. The IHRA (formerly the Task Force for International Cooperation on Holocaust Education, Remembrance and Research, or ITF) was initiated in 1998 by former Swedish Prime Minister Göran Persson. Today the IHRA network consists of over 40 countries as well as key international partner organizations with a mandate to deal with Holocaust-related issues. -
Pitolisant (Wakix) Reference Number: CP.PMN.221 Effective Date: 03.01.20 Last Review Date: 02.21 Line of Business: Commercial, HIM, Medicaid Revision Log
Clinical Policy: Pitolisant (Wakix) Reference Number: CP.PMN.221 Effective Date: 03.01.20 Last Review Date: 02.21 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description ® Wakix (pitolisant) is a selective histamine 3 (H3) receptor antagonist/inverse agonist. FDA Approved Indication(s) Wakix is indicated for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy. Policy/Criteria Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria. It is the policy of health plans affiliated with Centene Corporation® that Wakix is medically necessary when the following criteria are met: I. Initial Approval Criteria A. Narcolepsy with Cataplexy (must meet all): 1. Diagnosis of narcolepsy with cataplexy; 2. Prescribed by or in consultation with a neurologist or sleep medicine specialist; 3. Age ≥ 18 years; 4. Failure of 2 of the following antidepressants, each used for ≥ 1 month, unless member’s age is ≥ 65, clinically significant adverse effects are experienced, or all are contraindicated: venlafaxine, fluoxetine, atomoxetine, clomipramine, protriptyline; 5. Dose does not exceed 35.6 mg (two 17.8 mg tablets) per day. Approval duration: Medicaid/HIM – 12 months Commercial – Length of Benefit B. Narcolepsy with Excessive Daytime Sleepiness (must meet all): 1. Diagnosis of narcolepsy with EDS; 2. Prescribed by or in consultation with a neurologist or sleep medicine specialist; 3. Age ≥ 18 years; 4. Failure of a 1-month trial of one of the following central nervous system (CNS) stimulants at up to maximally indicated doses, unless clinically significant adverse effects are experienced or all are contraindicated: amphetamine immediate-release (IR), amphetamine, dextroamphetamine IR, dextroamphetamine, methylphenidate IR; *Prior authorization may be required for CNS stimulants Page 1 of 6 CLINICAL POLICY Pitolisant 5. -
Merlin Inhibits Wnt/Β-Catenin Signaling by Blocking LRP6 Phosphorylation
Cell Death and Differentiation (2016) 23, 1638–1647 & 2016 Macmillan Publishers Limited, part of Springer Nature. All rights reserved 1350-9047/16 www.nature.com/cdd Merlin inhibits Wnt/β-catenin signaling by blocking LRP6 phosphorylation M Kim1,6, S Kim1,6, S-H Lee2,3,6, W Kim1, M-J Sohn4, H-S Kim5, J Kim*,2 and E-H Jho*,1 Merlin, encoded by the NF2 gene, is a tumor suppressor that acts by inhibiting mitogenic signaling and is mutated in Neurofibromatosis type II (NF2) disease, although its molecular mechanism is not fully understood. Here, we observed that Merlin inhibited Wnt/β-catenin signaling by blocking phosphorylation of LRP6, which is necessary for Wnt signal transduction, whereas mutated Merlin in NF2 patients did not. Treatment with Wnt3a enhanced phosphorylation of Ser518 in Merlin via activation of PAK1 in a PIP2-dependent manner. Phosphorylated Merlin dissociated from LRP6, allowing for phosphorylation of LRP6. Tissues from NF2 patients exhibited higher levels of β-catenin, and proliferation of RT4-D6P2T rat schwannoma cells was significantly reduced by treatment with chemical inhibitors of Wnt/β-catenin signaling. Taken together, our findings suggest that sustained activation of Wnt/β-catenin signaling due to abrogation of Merlin-mediated inhibition of LRP6 phosphorylation may be a cause of NF2 disease. Cell Death and Differentiation (2016) 23, 1638–1647; doi:10.1038/cdd.2016.54; published online 10 June 2016 Wnt/β-catenin signaling has essential roles in the regulation of β-catenin is then translocated into nuclei to activate -
Histamine Receptors
Tocris Scientific Review Series Tocri-lu-2945 Histamine Receptors Iwan de Esch and Rob Leurs Introduction Leiden/Amsterdam Center for Drug Research (LACDR), Division Histamine is one of the aminergic neurotransmitters and plays of Medicinal Chemistry, Faculty of Sciences, Vrije Universiteit an important role in the regulation of several (patho)physiological Amsterdam, De Boelelaan 1083, 1081 HV, Amsterdam, The processes. In the mammalian brain histamine is synthesised in Netherlands restricted populations of neurons that are located in the tuberomammillary nucleus of the posterior hypothalamus.1 Dr. Iwan de Esch is an assistant professor and Prof. Rob Leurs is These neurons project diffusely to most cerebral areas and have full professor and head of the Division of Medicinal Chemistry of been implicated in several brain functions (e.g. sleep/ the Leiden/Amsterdam Center of Drug Research (LACDR), VU wakefulness, hormonal secretion, cardiovascular control, University Amsterdam, The Netherlands. Since the seventies, thermoregulation, food intake, and memory formation).2 In histamine receptor research has been one of the traditional peripheral tissues, histamine is stored in mast cells, eosinophils, themes of the division. Molecular understanding of ligand- basophils, enterochromaffin cells and probably also in some receptor interaction is obtained by combining pharmacology specific neurons. Mast cell histamine plays an important role in (signal transduction, proliferation), molecular biology, receptor the pathogenesis of various allergic conditions. After mast cell modelling and the synthesis and identification of new ligands. degranulation, release of histamine leads to various well-known symptoms of allergic conditions in the skin and the airway system. In 1937, Bovet and Staub discovered compounds that antagonise the effect of histamine on these allergic reactions.3 Ever since, there has been intense research devoted towards finding novel ligands with (anti-) histaminergic activity. -
Henry Jenkins Convergence Culture Where Old and New Media
Henry Jenkins Convergence Culture Where Old and New Media Collide n New York University Press • NewYork and London Skenovano pro studijni ucely NEW YORK UNIVERSITY PRESS New York and London www.nyupress. org © 2006 by New York University All rights reserved Library of Congress Cataloging-in-Publication Data Jenkins, Henry, 1958- Convergence culture : where old and new media collide / Henry Jenkins, p. cm. Includes bibliographical references and index. ISBN-13: 978-0-8147-4281-5 (cloth : alk. paper) ISBN-10: 0-8147-4281-5 (cloth : alk. paper) 1. Mass media and culture—United States. 2. Popular culture—United States. I. Title. P94.65.U6J46 2006 302.230973—dc22 2006007358 New York University Press books are printed on acid-free paper, and their binding materials are chosen for strength and durability. Manufactured in the United States of America c 15 14 13 12 11 p 10 987654321 Skenovano pro studijni ucely Contents Acknowledgments vii Introduction: "Worship at the Altar of Convergence": A New Paradigm for Understanding Media Change 1 1 Spoiling Survivor: The Anatomy of a Knowledge Community 25 2 Buying into American Idol: How We are Being Sold on Reality TV 59 3 Searching for the Origami Unicorn: The Matrix and Transmedia Storytelling 93 4 Quentin Tarantino's Star Wars? Grassroots Creativity Meets the Media Industry 131 5 Why Heather Can Write: Media Literacy and the Harry Potter Wars 169 6 Photoshop for Democracy: The New Relationship between Politics and Popular Culture 206 Conclusion: Democratizing Television? The Politics of Participation 240 Notes 261 Glossary 279 Index 295 About the Author 308 V Skenovano pro studijni ucely Acknowledgments Writing this book has been an epic journey, helped along by many hands. -
Http Www Cissusa Com Ciss Instruction Html
Http Www Cissusa Com Ciss Instruction Html Solute and argus-eyed Mika fullers her horehounds bunt invidiously or sterilised cutely, is Herrick Irazodiacal? is chartless Fruiting and Felipe overflies sometimes wit as toreutic rehearsing Niccolo his formularisingelectrum convexedly piratically and and damaged relaying sowherever. homiletically! But also affect urban wildlife This issue is really hard to pin do military struggles with this on many levels. To access the Web, you need a connection to the Internet. It is the President exemptions to his rich buddies. However, it has not been analysed yet in a systematic way in the context of urban biotope mapping. Nd whole rock isochron yielded Paleoproterozoic ages. Avoid injury to lower trunk as this can create an entrance for borers. The NCTE site presents information of value to classroom language arts teachers. The effects of climate change on the vegetation of Central European cites. Indian subcontinent, the Himalayas, and portions of Southeast Asia including Thailand, Vietnam, and Myanmar. Already you can find the ifj. Urban agriculture utilizing the ecocircle approach in disadvantaged communities in Potchefstroom, South Africa. Battleship, which is based on coordinate geometry. The statement of Deutschewitz et al. The two airlines argue that their merger would increase competition by creating another big competitor to Uni and Delta Air Lines, which grew through recent mergers. Spieth, who won his maiden PGA Tour title at the John Deere Classic in July to membership status. What is most commonly used to control insect pests? These days my head is full of curious information. Tajuria isaeus is a butterfly in the family Lycaenidae. -
Profile of Pitolisant in the Management of Narcolepsy: Design, Development, and Place in Therapy
Journal name: Drug Design, Development and Therapy Article Designation: Review Year: 2018 Volume: 12 Drug Design, Development and Therapy Dovepress Running head verso: Romigi et al Running head recto: Pitolisant and narcolepsy open access to scientific and medical research DOI: 101145 Open Access Full Text Article REVIEW Profile of pitolisant in the management of narcolepsy: design, development, and place in therapy Andrea Romigi1 Abstract: Narcolepsy is a rare sleep disorder characterized by excessive daytime sleepiness and Giuseppe Vitrani1 rapid eye movement sleep dysregulation, manifesting as cataplexy and sleep paralysis, as well Temistocle Lo Giudice1 as hypnagogic and hypnopompic hallucinations. Disease onset may occur at any age, although Diego Centonze1,2 adolescents and young adults are mainly affected. Currently, the diagnosis delay ranges from Valentina Franco3 8 to 10 years and drug therapy may only attenuate symptoms. Pitolisant is a first-in-class new drug currently authorized by the European Medicines Agency to treat narcolepsy with or without 1IRCCS Istituto Neurologico cataplexy in adults and with an expanded evaluation for the treatment of neurologic diseases such Mediterraneo Neuromed, Pozzilli (IS), Italy; 2Department of System as Parkinson’s disease and epilepsy. This article reviews the pharmacokinetic and pharmacody- Medicine, University of Rome Tor namic profile of pitolisant, highlighting its effectiveness and safety in patients with narcolepsy. Vergata Rome, Italy; 3IRCCS Mondino Foundation, Pavia, Italy We performed a systematic review of the literature using PubMed, Embase, and Google Scholar. We report on the efficacy and safety data of pitolisant in narcoleptic patients regarding cataplexy episodes and subjective and objective daytime sleepiness. The development program of pitolisant was characterized by eight Phase II/III studies. -
The Role of the C-Terminus Merlin in Its Tumor Suppressor Function Vinay Mandati
The role of the C-terminus Merlin in its tumor suppressor function Vinay Mandati To cite this version: Vinay Mandati. The role of the C-terminus Merlin in its tumor suppressor function. Agricultural sciences. Université Paris Sud - Paris XI, 2013. English. NNT : 2013PA112140. tel-01124131 HAL Id: tel-01124131 https://tel.archives-ouvertes.fr/tel-01124131 Submitted on 19 Mar 2015 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. 1 TABLE OF CONTENTS Abbreviations ……………………………………………………………………………...... 8 Resume …………………………………………………………………………………… 10 Abstract …………………………………………………………………………………….. 11 1. Introduction ………………………………………………………………………………12 1.1 Neurofibromatoses ……………………………………………………………………….14 1.2 NF2 disease ………………………………………………………………………………15 1.3 The NF2 gene …………………………………………………………………………….17 1.4 Mutational spectrum of NF2 gene ………………………………………………………..18 1.5 NF2 in other cancers ……………………………………………………………………...20 2. ERM proteins and Merlin ……………………………………………………………….21 2.1 ERMs ……………………………………………………………………………………..21 2.1.1 Band 4.1 Proteins and ERMs …………………………………………………………...21 2.1.2 ERMs structure ………………………………………………………………………....23 2.1.3 Sub-cellular localization and tissue distribution of ERMs ……………………………..25 2.1.4 ERM proteins and their binding partners ……………………………………………….25 2.1.5 Assimilation of ERMs into signaling pathways ………………………………………...26 2.1.5. A. ERMs and Ras signaling …………………………………………………...26 2.1.5. B. ERMs in membrane transport ………………………………………………29 2.1.6 ERM functions in metastasis …………………………………………………………...30 2.1.7 Regulation of ERM proteins activity …………………………………………………...31 2.1.7. -
Missense Mutations in the NF2 Gene Result in the Quantitative Loss of Merlin Protein and Minimally Affect Protein Intrinsic Function
Missense mutations in the NF2 gene result in the quantitative loss of merlin protein and minimally affect protein intrinsic function Chunzhang Yang, Ashok R. Asthagiri, Rajiv R. Iyer, Jie Lu, David S. Xu, Alexander Ksendzovsky, Roscoe O. Brady1, Zhengping Zhuang1, and Russell R. Lonser1 Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892 Contributed by Roscoe O. Brady, February 9, 2011 (sent for review December 29, 2010) Neurofibromatosis type 2 (NF2) is a multiple neoplasia syndrome Results and is caused by a mutation of the NF2 tumor suppressor gene Quantitative Tumor Suppressor Protein Levels and mRNA Expression. that encodes for the tumor suppressor protein merlin. Biallelic NF2 To assess the levels of merlin expression in NF2 tumors, we gene inactivation results in the development of central nervous quantitatively measured merlin expression in microdissected system tumors, including schwannomas, meningiomas, ependy- tumors from NF2 patients using Western blot analysis (Fig. 1A). momas, and astrocytomas. Although a wide variety of missense Quantitative protein analysis revealed a significant reduction in germline mutations in the coding sequences of the NF2 gene can merlin expression in NF2-associated meningiomas and schwan- cause loss of merlin function, the mechanism of this functional loss nomas (95% reduction in merlin expression; seven tumors) com- is unknown. To gain insight into the mechanisms underlying loss pared with normal adjacent central nervous system tissue. of merlin function in NF2, we investigated mutated merlin homeo- Consistent with Western blot analysis of merlin expression in NF2- stasis and function in NF2-associated tumors and cell lines. -
AUSTRALIAN PATENT OFFICE (11) Application No. AU 199875933 B2
(12) PATENT (11) Application No. AU 199875933 B2 (19) AUSTRALIAN PATENT OFFICE (10) Patent No. 742342 (54) Title Nucleic acid arrays (51)7 International Patent Classification(s) C12Q001/68 C07H 021/04 C07H 021/02 C12P 019/34 (21) Application No: 199875933 (22) Application Date: 1998.05.21 (87) WIPO No: WO98/53103 (30) Priority Data (31) Number (32) Date (33) Country 08/859998 1997.05.21 US 09/053375 1998.03.31 US (43) Publication Date : 1998.12.11 (43) Publication Journal Date : 1999.02.04 (44) Accepted Journal Date : 2001.12.20 (71) Applicant(s) Clontech Laboratories, Inc. (72) Inventor(s) Alex Chenchik; George Jokhadze; Robert Bibilashvilli (74) Agent/Attorney F.B. RICE and CO.,139 Rathdowne Street,CARLTON VIC 3053 (56) Related Art PROC NATL ACAD SCI USA 93,10614-9 ANCEL BIOCHEM 216,299-304 CRENE 156,207-13 OPI DAtE 11/12/98 APPLN. ID 75933/98 AOJP DATE 04/02/99 PCT NUMBER PCT/US98/10561 IIIIIIIUIIIIIIIIIIIIIIIIIIIII AU9875933 .PCT) (51) International Patent Classification 6 ; (11) International Publication Number: WO 98/53103 C12Q 1/68, C12P 19/34, C07H 2UO2, Al 21/04 (43) International Publication Date: 26 November 1998 (26.11.98) (21) International Application Number: PCT/US98/10561 (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, (22) International Filing Date: 21 May 1998 (21.05.98) GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, (30) Priority Data: TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO 08/859,998 21 May 1997 (21.05.97) US patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian 09/053,375 31 March 1998 (31.03.98) US patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, Fl, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, (71) Applicant (for all designated States except US): CLONTECH CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). -
International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors
1521-0081/67/3/601–655$25.00 http://dx.doi.org/10.1124/pr.114.010249 PHARMACOLOGICAL REVIEWS Pharmacol Rev 67:601–655, July 2015 Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics ASSOCIATE EDITOR: ELIOT H. OHLSTEIN International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors Pertti Panula, Paul L. Chazot, Marlon Cowart, Ralf Gutzmer, Rob Leurs, Wai L. S. Liu, Holger Stark, Robin L. Thurmond, and Helmut L. Haas Department of Anatomy, and Neuroscience Center, University of Helsinki, Finland (P.P.); School of Biological and Biomedical Sciences, University of Durham, United Kingdom (P.L.C.); AbbVie, Inc. North Chicago, Illinois (M.C.); Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany (R.G.); Department of Medicinal Chemistry, Amsterdam Institute of Molecules, Medicines and Systems, VU University Amsterdam, The Netherlands (R.L.); Ziarco Pharma Limited, Canterbury, United Kingdom (W.L.S.L.); Institute of Pharmaceutical and Medical Chemistry (H.S.) and Institute of Neurophysiology, Medical Faculty (H.L.H.), Heinrich-Heine-University Duesseldorf, Germany; and Janssen Research & Development, LLC, San Diego, California (R.L.T.) Abstract ....................................................................................602 Downloaded from I. Introduction and Historical Perspective .....................................................602 II. Histamine H1 Receptor . ..................................................................604 A. Receptor Structure